ArticleGeroScience2026
Sex and age-specific medication interaction in osteoporosis risk.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis, characterized by low bone mineral density (BMD) and increased fracture risk, is common yet underdiagnosed in older adults. Medications such as corticosteroids, levothyroxine, and antiepileptic drugs are well-documented contributors to BMD loss. This study examines how long-term use of these medications affects osteoporosis prevalence, specifically focusing on sex and age differences. This retrospective electronic health record study included adults aged 50-90 years. In the revised primary analysis, osteoporosis was defined using diagnosis codes only; osteoporosis screening codes and DXA procedure codes were excluded from the primary outcome. Associations between chronic exposure to corticosteroids, levothyroxine, or antiepileptics and osteoporosis ascertainment were estimated using modified Poisson regression with robust standard errors, adjusting for demographics, healthcare utilization, medication-specific indication diagnoses, and bone health covariates. Adjusted prevalence ratios and adjusted prevalence differences were reported. In the revised diagnosis-only analysis, associations were attenuated relative to the original broad outcome definition. Chronic corticosteroid exposure retained a positive but imprecise association with osteoporosis ascertainment (aPR 1.57, 95% CI 0.79-3.12; aPD +1.15 percentage points), whereas antiepileptic exposure (aPR 0.92, 95% CI 0.66-1.30; aPD -0.15 percentage points) and levothyroxine exposure (aPR 0.71, 95% CI 0.42-1.21; aPD -0.59 percentage points) were not associated with higher adjusted prevalence. Long-term use of corticosteroids, levothyroxine, or antiepileptics increases osteoporosis risk, with sex- and age-specific patterns. Men, especially younger ones, showed greater relative risk, while women exhibited higher absolute prevalence. These findings support targeted screening and early intervention strategies based on medication exposure, age, and sex.
Indexed as
Identifiers
42627439What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.